This Medudy course is a video tutorial for physicians on the topic of "Oral Anticoagulants in Atrial Fibrillation and Severe Chronic Kidney Disease", in which we summarize the latest and most important clinical studies for you.
Chronic kidney disease (CKD) increases the risk of cardiovascular complications, including atrial fibrillation (AF). Both conditions are associated with increased risks of thromboembolism and all-cause mortality. While direct oral anticoagulants, short DOACs, are recommended over warfarin for thromboprophylaxis in patients with AF, there is limited data on their safety and efficacy in individuals with severe CKD.
Today's study therefore compares the risks of major bleeding, stroke or systemic embolism, and mortality among different oral anticoagulants in patients with atrial fibrillation and severe chronic kidney disease.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used for better didactics. The people on which the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by Medudy's medical team.
At the end of this tutorial, you will know:
- the publication's background on why this research question is relevant
- the publication's study design and methods to answer this research question
- the publication's results and main takeaways
- the publication's conclusion as well as potential limitations